Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

12.21
-0.3100-2.48%
Post-market: 12.11-0.1000-0.82%19:26 EDT
Volume:2.07M
Turnover:25.45M
Market Cap:2.12B
PE:-9.54
High:12.71
Open:12.59
Low:12.07
Close:12.52
52wk High:12.91
52wk Low:5.79
Shares:174.00M
Float Shares:137.00M
Volume Ratio:1.33
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2802
EPS(LYR):-1.2227
ROE:-63.41%
ROA:-31.14%
PB:6.94
PE(LYR):-9.99

Loading ...

Don't Ignore The Insider Selling In Ocular Therapeutix

Simply Wall St.
·
Aug 30

Ocular Therapeutix Executives Cash In: Major Stock Sales Revealed!

TIPRANKS
·
Aug 28

Sanjay Nayak, Chief Strategy Officer, Reports Disposal of Common Shares in Ocular Therapeutix Inc

Reuters
·
Aug 28

Chief Scientific Officer Jeffrey S. Heier Reports Disposal of Common Shares of Ocular Therapeutix Inc

Reuters
·
Aug 28

Pravin Dugel, Director and Officer, Reports Disposal of Ocular Therapeutix Inc. Common Shares

Reuters
·
Aug 28

Ocular Therapeutix: Strategic Advancements and Market Potential Drive Buy Rating

TIPRANKS
·
Aug 12

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (Spa) for Registrational Trial of Axpaxli™ in Npdr

THOMSON REUTERS
·
Aug 12

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR

GlobeNewswire
·
Aug 12

Ocular Therapeutix (OCUL) Receives a Buy from RBC Capital

TIPRANKS
·
Aug 07

Ocular Therapeutix Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
Aug 07

Ocular Therapeutix price target lowered to $20 from $22 at Scotiabank

TIPRANKS
·
Aug 06

OCUL Sales Drop 18%

Motley Fool
·
Aug 06

Ocular Therapeutix Earnings Call: Positive Outlook Amid Trial Progress

TIPRANKS
·
Aug 06

Stock Track | Ocular Therapeutix Plummets 10.69% Pre-Market on Q2 Earnings Miss and Revenue Decline

Stock Track
·
Aug 05

Ocular Therapeutix Shares Fall 14% After Q2 Results

THOMSON REUTERS
·
Aug 05

Stock Track | Ocular Therapeutix Plunges 6.07% Pre-Market on Q2 Earnings Miss and Revenue Decline

Stock Track
·
Aug 05

Earnings Flash (OCUL) Ocular Therapeutix Posts Q2 Net Loss $0.39 a Share, vs. FactSet Est of $0.35 Loss

MT Newswires Live
·
Aug 05

Ocular Therapeutix Inc. Reports 18.1% Decrease in Q2 2025 Total Net Revenue, Cites Challenging Reimbursement Environment for DEXTENZA

Reuters
·
Aug 05

Ocular Therapeutix Q2 EPS $(0.39) Misses $(0.36) Estimate, Sales $13.459M Beat $13.253M Estimate

Benzinga
·
Aug 05

BRIEF-Ocular Therapeutix Q2 EPS USD -0.39

Reuters
·
Aug 05